Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.36 |
| ▸ | GZMB | P10144 | 2/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802264 | 0.84 | TASP1 (0.51) | TASP1CASP1 | |
| SCHEMBL29946268 | 0.82 | TASP1 (0.51) | TASP1ALDH1A1CASP1 | |
| SCHEMBL29923992 | 0.81 | TASP1 (0.48) | TASP1ALDH1A1CASP1EDNRACAPN1 | |
| SCHEMBL5493308 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PSMB5PSMB2CAPN1PSMB1 | |
| SCHEMBL5493312 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PSMB5PSMB2CAPN1PSMB1 | |
| SCHEMBL23924919 | 0.78 | TASP1 (0.52) | TASP1CASP1GZMB | |
| SCHEMBL20257131 | 0.78 | TASP1 (0.52) | TASP1CASP1GZMB | |
| SCHEMBL23132679 | 0.78 | TASP1 (0.52) | TASP1CASP1GZMB | |
| SCHEMBL23133165 | 0.78 | TASP1 (0.52) | TASP1CASP1GZMB | |
| SCHEMBL2381289 | 0.78 | TASP1 (0.52) | TASP1CASP1GZMB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215356-B2 | Methods of preparing a primary cell sample | CELCUITY INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230235293-A1 | METHODS OF PREPARING A PRIMARY CELL SAMPLE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11591573-B2 | Methods of preparing a primary cell sample | CELCUITY INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TASP1 2942/4885ALDH1A1 11/4885CASP1 72/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TASP1 2942/4885ALDH1A1 11/4885CASP1 72/4885 |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TASP1 2942/4885ALDH1A1 11/4885CASP1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.